Delving into the Latest Updates on Aztreonam lysine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AI, AZLI, Aztreonam lysine (USAN)

+ [5]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesCongenital DisordersDigestive System Disorders+ [2]

Active Indication

Cystic FibrosisInfectious Lung DisorderNon-cystic fibrosis bronchiectasis+ [1]

Inactive Indication

Burkholderia InfectionsGram-Negative Bacterial InfectionsPseudomonas aeruginosa infection+ [1]

Originator Organization

Gilead Sciences, Inc.

Active Organization

Gilead Sciences Ireland UC

Oregon Health & Science University

Gilead Sciences, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (21 Sep 2009),

Cystic FibrosisInfectious Lung Disorder

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H31N7O10S2

InChIKeyKPPBAEVZLDHCOK-JHBYREIPSA-N

CAS Registry827611-49-4

View All Structures (2)

Intrinsically active rhamnolipids functionalized liposomes (rhamnosomes) as a carrier for cinnamaldehyde were developed to enhance the antibacterial activity against foodborne Salmonella isolates.Stable rhamnosomes were optimized with an excellent encapsulation efficiency of 85 ± 1%.SEM revealed slightly rough surface morphol. and the mean diameter was slightly increased after the incorporation of cinnamaldehyde in rhamnosomes from 77 to 137 ± 2 nm.However, neg. zeta-potential values were reduced from -18.2 ± 4 mV to - 13.4 ± 2 mV for cinnamaldehyde-loaded rhamnosomes.FTIR analyses revealed chem. interactions between rhamnolipids and phospholipids, which facilitated the development of rhamnosomes.Cinnamaldehyde-loaded rhamnosomes exhibited higher anti-Salmonella activity as compared to free cinnamaldehyde and void-rhamnosomes, and 75-80% reduction in biomass was observed due to their enhanced binding with the bacterial membrane in the antibiofilm assays.Antimicrobial results revealed that cinnamaldehyde-loaded rhamnosomes inhibited bacterial growth, displayed adequate biocompatibility and stability while providing an innovative strategy to control foodborne-resistant pathogens.

01 Mar 2025·Proceedings of the National Academy of Sciences, India Section B: Biological Sciences

Antibiotic Resistance Profile, Multidrug-, Extensively drug-, and Pandrug-Resistant Bacterial Isolates: Hemagglutination and Hemolytic Activities against Human Erythrocytes

Author: Akinjogunla, Olajide J. ; Oshosanya, Godwin O. ; Adefiranye, Oyetayo O. ; Adenugba, Imabong T. ; Edem, Ekom N. ; Ogboona, Faith C.

The classification of bacteria as multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) are epidemiol. significant for the assessment of bacterial resistance to antibiotics in geog. regions.This study determined the occurrence of MDR-, XDR-, and PDR-bacteria in clin. samples using the standard protocol, disk diffusion method, and VITEK 2 automated system, and evaluated the hemolytic and hemagglutination activities of the bacterial isolates using blood agar and human erythrocyte suspensions of known blood groups A, B, and O (Rhesus +) washed with phosphate buffer saline.Of the 314 isolates from urine, 9.6 and 4.1% were XDR and PDR, resp.Isolates from the wound and blood were highly resistant to amoxicillin and tetracycline; E. faecalis from the stool was highly resistant to amoxicillin and tetracycline, while P. aeruginosa showed a low resistance to streptomycin and aztreonam.Hemagglutination activities against blood groups A⁺, B⁺, AB⁺, and O⁺ were pos. in 67.2, 51.6, 56.1, and 44.9% of urine isolates, resp.; 57.4% of MDR isolates from wounds agglutinated blood A⁺ group cells, 48.9% agglutinated blood AB⁺ group cells, and 40% agglutinated blood O⁺.Of the 187 blood isolates, 58.8, 40.6, 48.1, and 39% were pos. for hemagglutination activities against blood groups A⁺, B⁺, AB⁺, and O⁺, resp.; 45% of the isolates from stools hemolyzed blood group A⁺ cells, while < 40% of the isolates hemolyzed blood group B⁺, AB⁺, and O⁺ cells.This study has shown the significance of using appropriate human RBCs when studying the hemagglutination and hemolytic activity of pathogenic bacterial isolates.

01 Mar 2025·European Journal of Hospital Pharmacy

Inhaled aztreonam lysine in the management ofPseudomonas aeruginosain patients with cystic fibrosis: real-life effectiveness

Article

Author: Gartner, Silvia ; Álvarez-Fernández, Antonio ; Fernández-Polo, Aurora ; Roch-Santed, María ; Cañete-Ramírez, Carme ; Monte-Boquet, Emilio ; Luna-Paredes, Carmen ; Jiménez-Lozano, Inés

BACKGROUNDInhaled antibiotics have achieved or stabilised the clinical condition of patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection. We aimed to determine the effectiveness of aztreonam lysine inhaled solution (AZLI) in patients with CF and chronic P. aeruginosa infection.METHODSA retrospective observational study was conducted on patients with CF and chronic P. aeruginosa infection who received AZLI between July 2012 and September 2018 inclusive in three Spanish hospitals in a routine clinical practice setting. The primary endpoint was the absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV₁) compared with the previous 12 months, at the start of AZLI treatment and 12 months after starting the drug. Other variables analysed were exacerbations, hospitalisations, type and route of antibiotics prescribed, weight and body mass index (BMI) and adverse drug reactions.RESULTSIn a cohort of 52 patients, AZLI treatment led to stabilisation of FEV₁, changing from a mean (SD) value of 55.60 (21.3)% at the start of treatment to 56.8 (20.4)% after 12 months of treatment (p=0.5296) in patients who had not previously received the drug. In addition, it significantly reduced exacerbations from a median (P25; P75) of 2.0 (1.0; 3.0) in the 12 months prior to AZLI to 1.0 (1.0; 2.0) in the 12 months after treatment initiation (p=0.0350). AZLI also reduced the need for other antibiotics and prevented a decrease in BMI, with an adequate safety profile.CONCLUSIONSAZLI achieved stabilisation of lung function measured by FEV₁ in patients with CF and chronic P. aeruginosa infection, along with an adequate safety profile.

100 Deals associated with Aztreonam lysine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06558	-	J01DF01	DB00355

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cystic Fibrosis	European Union	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	Norway	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	Iceland	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	Liechtenstein	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	European Union	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	Liechtenstein	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	Iceland	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	Norway	Gilead Sciences Ireland UC	21 Sep 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystic Fibrosis	Preclinical	United States	Gilead Sciences, Inc.	01 Feb 2005
Burkholderia Infections	Discovery	United States	Gilead Sciences, Inc.	01 Feb 2010
Burkholderia Infections	Discovery	Canada	Gilead Sciences, Inc.	01 Feb 2010
Infectious Lung Disorder	Discovery	Canada	Gilead Sciences, Inc.	01 May 2008
Infectious Lung Disorder	Discovery	Australia	Gilead Sciences, Inc.	01 May 2008
Infectious Lung Disorder	Discovery	United States	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Discovery	Australia	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Discovery	Canada	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Discovery	United States	Gilead Sciences, Inc.	01 May 2008
Cystic Fibrosis	Discovery	United States	Gilead Sciences, Inc.	01 Feb 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03219164 (ALPINE2 \| ALPINE 2, CTgov)	Phase 3	Pseudomonas aeruginosa infection \| Cystic Fibrosis	149	Placebo+AZLI (AZLI 14 Days + Placebo 14 Days)	xhiorkksgk(dzlkpwzwtu) = zrmmwxstkl hxlqlqskvh (oxaddkfgbd, hhttbpksum - xubqadgzpb) View more	-	16 May 2022
				aztreonam (AZLI 28 Days)	xhiorkksgk(dzlkpwzwtu) = lznaoixxao hxlqlqskvh (oxaddkfgbd, hmyaoyzfeo - bsrcmgjruu) View more
CSCO2021	Not Applicable	Soft Tissue Sarcoma	28	安罗替尼+AI	waheevucrv(mffeqilgvf) = 67.86% nclifclpuv (gqvhuhysse ) View more	-	25 Sep 2021
NCT01641822 (AZLI CAT, CTgov)	Phase 3	Pseudomonas Infections \| Cystic Fibrosis \| Infectious Lung Disorder	107	Tobramycin inhalation solution+AZLI (AZLI)	vsmkoydzyt(byhslnzfgg) = poxmmpkipj jsstsvwpru (wlwenhuyha, ofesffsrsc - acmishturr) View more	-	09 May 2016
				Placebo to match AZLI+Tobramycin inhalation solution (Placebo)	vsmkoydzyt(byhslnzfgg) = cgdwzwtkhw jsstsvwpru (wlwenhuyha, rgvnmsenye - yixgyepfqi) View more
NCT01404234 (PALS, CTgov)	Phase 3	Pseudomonas Infections \| Cystic Fibrosis	61	AZLI	oahghesorx(gysmdywzmi) = kovlvfwbjx ccmciitmqm (qppaoivsen, sceiivcunx - gayzuvhfeb) View more	-	01 May 2014
NCT01314716 (AIR-BX2, CTgov)	Phase 3	Non-cystic fibrosis bronchiectasis \| Gram-Negative Bacterial Infections	274	AZLI (AZLI-AZLI)	cufentbbai(kxznbatmof) = qzftzczjew cbpjozjnpw (zplyvxview, zmbhpyhmef - pygpvjamrh) View more	-	16 Apr 2014
				Placebo+AZLI (Placebo-AZLI)	cufentbbai(kxznbatmof) = ranjryaemn cbpjozjnpw (zplyvxview, acqbygpsvn - fvynlezrwn) View more
NCT01313624 (AIR-BX1, CTgov)	Phase 3	Non-cystic fibrosis bronchiectasis \| Gram-Negative Bacterial Infections	266	AZLI (AZLI-AZLI)	wiymncwohw(rqeaoixejm) = ukavkivhqv ymgfcintka (bkxzupqemr, wgphfdvdkd - qlhvziiomg) View more	-	16 Apr 2014
				Placebo+AZLI (Placebo-AZLI)	wiymncwohw(rqeaoixejm) = ysbyqqhcfv ymgfcintka (bkxzupqemr, zadwcgxmtx - bnyetnymct) View more
NCT00805025 (CTgov)	Phase 2	Bronchiectasis	89	AZLI	oshatijhve(ayzrkviuvq) = ccvrkxkjkt jarbxcrnew (yamfvvsrpn, rbaxchfngs - hsjqiulxrf) View more	-	20 Mar 2014
NCT01059565 (CTgov)	Phase 3	Cystic Fibrosis \| Burkholderia Infections	102	AZLI (AZLI)	okwyosvsoo(baqnhfapwn) = owqrtizwwm xyafkvaoaz (dnwcfqquti, tvaasczbmq - ghrzqvdzoe) View more	-	11 Mar 2014
				Placebo (Placebo)	okwyosvsoo(baqnhfapwn) = vbercomnzt xyafkvaoaz (dnwcfqquti, zlfttsxvqi - krnstujqsa) View more
NCT00112359 (AIR-CF1, CTgov)	Phase 3	Cystic Fibrosis	166	Placebo (Placebo TID)	hywmlbwrvu(nxgpwkopwb) = pwfytirbjf rrlwmwqkfx (vbqvhkxpge, sqaqimzbpu - wizwmtyohe) View more	-	21 Apr 2011
				AZLI (75 mg AZLI TID)	hywmlbwrvu(nxgpwkopwb) = kfdfepknvi rrlwmwqkfx (vbqvhkxpge, cloceanzps - xayytkhtcs) View more
NCT00104520 (AIR-CF2, CTgov)	Phase 3	Cystic Fibrosis	211	Placebo (Placebo (Pooled BID/TID))	qhkghguszb(fruxavgyng) = wldjrpxwuw lbofrcfxxw (gqsutwmvro, hrkhdwontu - pnktsoeugh) View more	-	11 Mar 2011
				AZLI (AZLI (Pooled BID/TID))	qhkghguszb(fruxavgyng) = fjkgwerzhr lbofrcfxxw (gqsutwmvro, krkosjfooq - uyzsornysf) View more